Short Interest in Heart Test Laboratories, Inc. (NASDAQ:HSCS) Increases By 6.1%

Posted by Teresa Graham on Jan 21st, 2025

Heart Test Laboratories, Inc. (NASDAQ:HSCS – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 31,200 shares, a growth of 6.1% from the December 15th total of 29,400 shares. Approximately 3.8% of the shares of the company are sold short. Based on an average trading volume of 42,900 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Ascendiant Capital Markets reiterated a “buy” rating and issued a $15.00 price target on shares of Heart Test Laboratories in a research note on Monday, September 23rd. Maxim Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of Heart Test Laboratories in a research report on Wednesday, December 18th.

Get Our Latest Stock Report on Heart Test Laboratories

Heart Test Laboratories Stock Up 4.2 %

HSCS stock opened at $3.47 on Tuesday. The company has a market cap of $3.40 million, a price-to-earnings ratio of -0.44 and a beta of 2.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.52 and a current ratio of 1.72. The business’s 50-day moving average is $3.43 and its two-hundred day moving average is $3.51. Heart Test Laboratories has a fifty-two week low of $2.36 and a fifty-two week high of $18.50.

Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) last released its quarterly earnings results on Monday, December 16th. The company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($2.30) by $0.03. During the same quarter in the previous year, the business posted ($15.92) EPS. As a group, analysts forecast that Heart Test Laboratories will post -9.82 earnings per share for the current year.

Heart Test Laboratories Company Profile

(Get Free Report)

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.